Clinical Trials Logo
  1. Home
  2. Hyperhidrosis
  3. NCT00168480
  4. Details
NCT00168480 Clinical Trial

A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis

Hyperhidrosis Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00168480
Other study ID # 191622-513
Secondary ID
Status Completed
Phase Phase 4
First received September 13, 2005
Last updated September 26, 2008
Start date November 2003
Est. completion date April 2007

Study information
Verified date September 2008
Source Allergan
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a three year open-label study in subjects with axillary hyperhidrosis.

Recruitment information / eligibility
Status Completed
Enrollment 424
Est. completion date April 2007
Est. primary completion date April 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Marked axillary hyperhidrosis

Exclusion Criteria:

- Previous use of botulinum toxin for hyperhidrosis

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Biological:
• Botulinum Toxin Type A
100 U, repeated treatments at > 4 month intervals up to Month 32, over a 36-month study period

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Allergan

Countries where clinical trial is conducted

United States,  Germany,  Sweden,  United Kingdom, 

Outcome
Type Measure Description Time frame Safety issue
Primary Assessment of axillary sweat production Every 4 Months No
Secondary Patient reported health outcome measures 1 Month Post-Treatment Visit No
See also
  Status Clinical Trial Phase
Completed NCT04924036 - Qbrexza Cloths for Hyperhidrosis of Amputation Sites Phase 2
Recruiting NCT05102396 - Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect? Phase 2
Recruiting NCT04178161 - Image Guided Targeted Photoablation for the Treatment of Localized Hyperhidrosis N/A
Completed NCT02552199 - A Non-Interventional Study To Assess Sweating
Completed NCT02565732 - Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis Phase 2
Recruiting NCT01930604 - Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis Phase 2
Completed NCT01811004 - Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis N/A
Completed NCT01671800 - Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating Phase 1
Completed NCT01956591 - Long Term Results of the Use of Oxybutynin for the Treatment of Hyperhidrosis N/A
Completed NCT01934153 - Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects Phase 1
Completed NCT06113978 - Thoracoscopic Sympathetic Chain Interruption for Palmar Hyperhidrosis in Patients Below 18 N/A
Completed NCT05247333 - Implementation of a Minor Ailment Service in Community Pharmacy Practice N/A
Completed NCT04906655 - An Open Label Study for Palmar Hyperhydrosis Phase 2
Completed NCT02563899 - Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis Phase 2
Withdrawn NCT05546710 - miraDry Post Market Tumescent Anesthesia Study N/A
Completed NCT02016885 - A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis Phase 2
Completed NCT03416348 - Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2 Phase 1
Completed NCT02973659 - The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar. N/A
Recruiting NCT05805696 - Treatment and Mapping of Impostor Phenomenon N/A
Completed NCT03816046 - Hyperhydrosis Treatment Using Botulinum Toxin Phase 4